Skip to main content
SpringerLink
Log in

Mycophenolate mofetil or tacrolimus compared with azathioprine in long-term maintenance treatment for active lupus nephritis

  • Research Article
  • Published:
Frontiers of Medicine Aims and scope Submit manuscript

Abstract

This study aimed to evaluate the efficacy and safety of mycophenolate mofetil (MMF) or tacrolimus (TAC) compared with azathioprine (AZA) as maintenance therapy for active lupus nephritis (ALN). Patients with ALN who responded to 24 weeks of induction treatment were enrolled. Patients who received MMF or TAC as induction therapy continued MMF or TAC treatment during the maintenance period, whereas those who received intravenous cyclophosphamide were subjected to AZA treatment. The primary endpoint was the incidence of renal relapse. Secondary endpoints included extrarenal flares and composite endpoints (deaths, end-stage renal disease, or doubling of serum creatinine levels). A total of 123 ALN patients (47 in the MMF group, 37 in the TAC group, and 39 in the AZA group) were enrolled. The median follow-up time was 60 months. Ten MMF-treated patients, ten TAC-treated patients, and eight AZA-treated patients experienced renal relapses (P = 0.844). The cumulative renal relapse rates in the MMF group (P = 0.934) and TAC group (P = 0.673) were similar to the renal relapse rate in the AZA group. No significant difference in the incidence of severe adverse event was observed among the groups. Long-term maintenance therapies with MMF or TAC might have similarly low rates of renal relapse and similar safety profiles compared with AZA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bomback AS, Appel GB. Updates on the treatment of lupus nephritis. J Am Soc Nephrol 2010; 21(12): 2028–2035

    Article  CAS  PubMed  Google Scholar 

  2. Danila MI, Pons-Estel GJ, Zhang J, Vilá LM, Reveille JD, Alarcón GS. Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort. Rheumatology (Oxford) 2009; 48(5): 542–545

    Article  Google Scholar 

  3. Campbell R Jr, Cooper GS, Gilkeson GS. Two aspects of the clinical and humanistic burden of systemic lupus erythematosus: mortality risk and quality of life early in the course of disease. Arthritis Rheum 2008; 59(4): 458–464

    Article  PubMed  Google Scholar 

  4. Tektonidou MG, Dasgupta A, Ward MM. Risk of end-stage renal disease in patients with lupus nephritis, 1971–2015: a systematic review and Bayesian meta-analysis. Arthritis Rheumatol 2016; 68 (6): 1432–1441

    Article  PubMed  PubMed Central  Google Scholar 

  5. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, Lau CS, Wong AK, Tong MK, Chan KW, Lai KN; Hong Kong-Guangzhou Nephrology Study Group. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000; 343(16): 1156–1162

    Article  CAS  PubMed  Google Scholar 

  6. Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, Garrido Ed ER, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46(8): 2121–2131

    Article  CAS  PubMed  Google Scholar 

  7. Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, Eitner F, Appel GB, Contreras G, Lisk L, Solomons N; ALMS Group. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011; 365(20): 1886–1895

    Article  CAS  PubMed  Google Scholar 

  8. Houssiau FA, D’Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R, Fiehn C, de Ramon Garrido E, Gilboe IM, Tektonidou M, Blockmans D, Ravelingien I, le Guern V, Depresseux G, Guillevin L, Cervera R; MAINTAIN Nephritis Trial Group. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010; 69(12): 2083–2089

    Article  CAS  PubMed  Google Scholar 

  9. Bensman A, Niaudet P. Non-immunologic mechanisms of calcineurin inhibitors explain its antiproteinuric effects in genetic glomerulopathies. Pediatr Nephrol 2010; 25(7): 1197–1199

    Article  PubMed  Google Scholar 

  10. Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, Chang JM, Choi HY, Campbell KN, Kim K, Reiser J, Mundel P. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008; 14(9): 931–938

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Chen W, Liu Q, Chen W, Tang X, Fu P, Liu F, Liao Y, Yang Z, Zhang J, Chen J, Lou T, Fu J, Kong Y, Liu Z, Li Z, Yu X. Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicenter randomized clinical trial. Lupus 2012; 21(9): 944–952

    Article  CAS  PubMed  Google Scholar 

  12. Li X, Ren H, Zhang Q, Zhang W, Wu X, Xu Y, Shen P, Chen N. Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol Dial Transplant 2012; 27(4): 1467–1472

    Article  CAS  PubMed  Google Scholar 

  13. Kamanamool N, Ingsathit A, Rattanasiri S, Ngamjanyaporn P, Kasitanont N, Chawanasuntorapoj R, Pichaiwong W, Anutrakulchai S, Sangthawan P, Ophascharoensuk V, Avihingsanon Y, Sumethkul V. Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial. Lupus 2018; 27(4): 647–656

    Article  CAS  PubMed  Google Scholar 

  14. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O’Nan P, Roth D. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350(10): 971–980

    Article  CAS  PubMed  Google Scholar 

  15. Mosca M, Bencivelli W, Neri R, Pasquariello A, Batini V, Puccini R, Tavoni A, Bombardieri S. Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis. Kidney Int 2002; 61(4): 1502–1509

    Article  PubMed  Google Scholar 

  16. Ioannidis JP, Boki KA, Katsorida ME, Drosos AA, Skopouli FN, Boletis JN, Moutsopoulos HM. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000; 57(1): 258–264

    Article  CAS  PubMed  Google Scholar 

  17. Mok CC, Ho CT, Chan KW, Lau CS, Wong RW. Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum 2002; 46(4): 1003–1013

    Article  CAS  PubMed  Google Scholar 

  18. Isenberg D, Appel GB, Contreras G, Dooley MA, Ginzler EM, Jayne D, Sánchez-Guerrero J, Wofsy D, Yu X, Solomons N. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford) 2010; 49(1): 128–140

    Article  Google Scholar 

  19. Yamamoto K, Okada Y, Nakamura K, Hiromura K, Nojima Y, Nakamura T. Inosine triphosphate pyrophosphatase 94C > A polymorphism: clinical implications for patients with systemic lupus erythematosus treated with azathioprine. Expert Opin Drug Saf 2010; 9(3): 447–457

    Article  CAS  PubMed  Google Scholar 

  20. Chen W, Tang X, Liu Q, Chen W, Fu P, Liu F, Liao Y, Yang Z, Zhang J, Chen J, Lou T, Fu J, Kong Y, Liu Z, Fan A, Rao S, Li Z, Yu X. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am J Kidney Dis 2011; 57(2): 235–244

    Article  CAS  PubMed  Google Scholar 

  21. Tanaka H, Watanabe S, Aizawa-Yashiro T, Oki E, Kumagai N, Tsuruga K, Ito E. Long-term tacrolimus-based immunosuppressive treatment for young patients with lupus nephritis: a prospective study in daily clinical practice. Nephron Clin Pract 2012; 121(3–4): c165–c173

    CAS  PubMed  Google Scholar 

  22. Moroni G, Quaglini S, Maccario M, Banfi G, Ponticelli C. “Nephritic flares” are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 1996; 50(6): 2047–2053

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The present study was supported by the National Natural Science Foundation of China (No. 81170671), Shanghai Health and Family Planning Committee Hundred Talents Program (No. 2018BR37). The investigators wish to thank the study participants and individuals who made the trial possible.

Author information

Author notes

  1. Qianying Zhang and Peng Xing contributed equally to this work.

Authors and Affiliations

  1. Department of Nephrology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China

    Qianying Zhang, Peng Xing, Hong Ren, Xiaonong Chen, Jingyuan Xie, Wen Zhang, Pingyan Shen, Xiao Li & Nan Chen

Authors
  1. Qianying Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peng Xing
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hong Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiaonong Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jingyuan Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wen Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Pingyan Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xiao Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Nan Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiao Li.

Ethics declarations

Qianying Zhang, Peng Xing, Hong Ren, Xiaonong Chen, Jingyuan Xie, Wen Zhang, Pingyan Shen, Xiao Li, and Nan Chen declare that they have no conflict of interest. The study was approved by the Ethics Committees of Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, and the registration number in the Chinese Clinical Trial Registry is ChiCTR-TRC-10000896. All patients signed written informed consent forms.

Electronic Supplementary Material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, Q., Xing, P., Ren, H. et al. Mycophenolate mofetil or tacrolimus compared with azathioprine in long-term maintenance treatment for active lupus nephritis. Front. Med. 16, 799–807 (2022). https://doi.org/10.1007/s11684-021-0849-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11684-021-0849-2

Keywords

Search

Navigation